Erythema nodosum, zoster duplex and pityriasis rosea as possible cutaneous adverse effects of Oxford-AstraZeneca COVID-19 vaccine: report of three cases from India

As a response to the coronavirus disease (COVID-19) pandemic, several vaccines have been developed globally and are being rolled out at a fast pace for public immunization. Drug controller general of India has approved use of Covaxin (BBV152, manufactured by Bharat Biotech) and Covishield (Oxford-AstraZeneca COVID-19 vaccine, manufactured by Serum Institute of India) for restricted use in emergency situation. We describe three cases of Covishield induced minor cutaneous adverse effects.